80 completed, 19 unknown, 15 recruiting, 13 terminated. 145 Phase 3, 29 Phase 2.
Follow Apnea: new trials by email Literature Review of Apnea trials Research Report on Apnea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| UBT251 Injection Phase Ⅲ Study (OSA-NPAP) UBT251, Placebo - Obstructive Sleep Apnea, Obesity | Phase 3 | Not yet recruiting | The United Bio-Technology (Hengqin) Co., Ltd. | 150 | 2026-12-01 | 2026-11-03 |
| A Study Of Synthetic THC And Sleep Dronabinol, Placebo - Obstructive Sleep Apnea | Phase 2 / Phase 3 | Not yet recruiting | Mayo Clinic | 72 | 2026-11-01 | 2026-09-18 |
| A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2) Berobenatide, Placebo - Apnea, Sleep Disorders | Phase 3 | Recruiting | Pfizer | 258 | 2026-10-19 | 2026-11-06 |
| UBT251 Injection Phase Ⅲ Study (OSA-PAP) UBT251, Placebo - Obstructive Sleep Apnea, Obesity | Phase 3 | Not yet recruiting | The United Bio-Technology (Hengqin) Co., Ltd. | 150 | 2026-10-10 | 2026-09-08 |
| Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea Continuous Positive Airway Pressure, Tirzepatide - Sleep Apnoea, Obesity & Overweight | Phase 2 / Phase 3 | Not yet recruiting | Woolcock Institute of Medical Research | 256 | 2026-10-01 | 2026-11-02 |
| A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1) Berobenatide, Placebo - Apnea, Sleep Disorders | Phase 3 | Recruiting | Pfizer | 258 | 2026-09-17 | 2026-11-05 |
| A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Receiving Positive Airway Pressure (PAP) Therapy HDM1005, Placebo - Obstructive Sleep Apnea (OSA) and Obesity | Phase 3 | Not yet recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 200 | 2026-09-01 | 2026-08-31 |
| A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Not Receiving Positive Airway Pressure (PAP) Therapy HDM1005, Placebo - Obstructive Sleep Apnea (OSA) and Obesity | Phase 3 | Not yet recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 200 | 2026-08-01 | 2026-08-26 |
| Non-invasive Ventilation or CPAP in OSA-COPD Following Admission for an Acute Hypercapnic Respiratory Failure Non-invasive Ventilation (NIV), Continous Positive Airway Pressure (CPAP) - Chronic Obstructive Pulmonary Disease Exacerbation, Obstructive Sleep Apnea Exacerbation | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 386 | 2026-06-03 | 2026-06-09 |
| Continuous Positive Airway Pressure, Arousability and Links to Mechanisms in Obstructive Sleep Apnea Eszopiclone, Placebo - Sleep Apnea, Obstructive Sleep Apnea | Phase 3 | Recruiting | Yale University | 250 | 2026-05-18 | 2026-06-03 |
| AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea NNC0487-0111, Placebo (matched to NNC0487-0111) - Obesity, Overweight | Phase 3 | Recruiting | Novo Nordisk A/S | 300 | 2026-05-05 | 2026-09-11 |
| AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea NNC0487-0111, Placebo (matched to NNC0487-0111) - Obesity, Overweight | Phase 3 | Recruiting | Novo Nordisk A/S | 300 | 2026-05-05 | 2026-10-07 |
| Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Receiving Positive Airway Pressure (PAP) Therapy GZR18 injection, Placebo - Obstructive Sleep Apnea (OSA) | Phase 3 | Recruiting | Gan & Lee Pharmaceuticals. | 140 | 2026-04-29 | 2026-11-12 |
| Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) Therapy Placebo, GZR18 injection - Obstructive Sleep Apnea (OSA) | Phase 3 | Recruiting | Gan & Lee Pharmaceuticals. | 140 | 2026-04-22 | 2026-11-12 |
| A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy XW003 injection, placebo with matching volume - OSA - Obstructive Sleep Apnea, Obesity | Phase 3 | Recruiting | Hangzhou Sciwind Biosciences Co., Ltd. | 140 | 2026-03-02 | 2026-08-28 |
| A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight Eloralintide, Placebo - Sleep Apnea, Obstructive, Obesity | Phase 3 | Recruiting | Eli Lilly and Company | 800 | 2026-02-10 | 2026-11-04 |
| A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy XW003 injection, placebo with matching volume - OSA - Obstructive Sleep Apnea, Obesity | Phase 3 | Recruiting | Hangzhou Sciwind Biosciences Co., Ltd. | 140 | 2026-02-09 | 2026-08-28 |
| Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy Maridebart cafraglutide, Placebo - Obesity, Obstructive Sleep Apnea | Phase 3 | Active not recruiting | Amgen | 250 | 2025-12-19 | 2026-10-06 |
| Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy Maridebart cafraglutide, Placebo - Obstructive Sleep Apnea | Phase 3 | Active not recruiting | Amgen | 250 | 2025-11-25 | 2026-09-29 |
| Mandibular Advancement Devices for Reflux in Obstructive Sleep Apnea Mandibular Advancement Device, Lower Oral Device Without Mandibular Advancement - Gastroesophageal Reflux Disease | Phase 3 | Not yet recruiting | Tuiuti University of Paraná | 40 | 2025-08-01 | 2025-07-08 |
Showing 20 of 145. Sign in to see all of them.
Sleep Apnea, Obstructive (99) · Sleep Apnea Syndromes (46) · Obesity (28) · Hypertension (16) · Disorders of Excessive Somnolence (13) · Hypoxia (8) · Overweight (8) · Hypercapnia (5) · Narcolepsy (5) · Pain (5) · Cardiovascular Diseases (4) · Dyslipidemias (4) · Heart Failure (4) · Premature Birth (4)
Respiration Disorders (145) · Respiratory Tract Diseases (145) · Nervous System Diseases (131) · Dyssomnias (130) · Sleep Disorders, Intrinsic (130) · Sleep Wake Disorders (126) · Sleep Apnea Syndromes (84) · Pathological Conditions, Signs and Symptoms (61) · Signs and Symptoms (53) · Nutritional and Metabolic Diseases (35) · Overnutrition (30) · Nutrition Disorders (29) · Body Weight (28) · Mental Disorders (22)
Modafinil (8) · Continuous Positive Airway Pressure (6) · caffeine citrate (6) · Dexmedetomidine (5) · pitolisant (4) · solriamfetol (4) · Acetazolamide (3) · Amlodipine (3) · BID protein, human (3) · Morphine (3) · Occlusal Splints (3) · lorcaserin (3) · montelukast (3) · Amiloride (2) · Chlorthalidone (2)
Cephalon (7) · VA Office of Research and Development (5) · Bioprojet (4) · Centro Universitario La Salle (4) · Eli Lilly and Company (4) · Apnex Medical, Inc. (3) · Apnimed (3) · Assistance Publique - Hôpitaux de Paris (3) · Eisai Inc. (3) · Jazz Pharmaceuticals (3) · Novo Nordisk A/S (3) · University of Manitoba (3) · University of Sao Paulo (3) · Amgen (2) · Clayton Sleep Insititute (2)
United States (61) · Canada (28) · France (18) · Spain (17) · China (15) · Australia (14) · Germany (14) · Brazil (13) · India (7) · Japan (6) · Netherlands (6) · United Kingdom (6) · Poland (5) · Hungary (4) · Taiwan (4)
Carl J Stepnowsky, PhD (2) · Evelyne De Paillette, MD (2) · Ruben E Alvaro, MD (2) · Aaron Chiu, MD (1) · Alexander Hincker, MD (1) · Alexandr Yu Litvin, MD (1) · Alfonso Solimano, MD (1) · Ali El-Solh, MD, MPH (1) · Ann Romaker, MD (1) · Anne Smits, MD, PhD (1) · Antonios Michalos, M.D., M.S. (1)
PMID 23661689, PMID 27206567, PMID 27659698, PMID 27888609, PMID 27116910, PMID 37979718, PMID 16707748, PMID 17441783, PMID 17513285, PMID 17989382, PMID 18853696, PMID 19122865, PMID 19234106, PMID 19926098, PMID 20647200, PMID 20705223, PMID 21173002, PMID 21358846, PMID 21358847, PMID 21372306, PMID 21795446, PMID 21801857, PMID 21885958, PMID 22043118, PMID 22253394, PMID 22334806, PMID 22334808, PMID 22421927, PMID 22968110, PMID 23204602, PMID 23227139, PMID 23598607, PMID 23690688, PMID 24127141, PMID 24293768, PMID 24382030, PMID 24401051, PMID 24445955, PMID 24458967, PMID 24496539, PMID 24634638, PMID 24808886, PMID 24840756, PMID 24910546, PMID 24916094, PMID 24947878, PMID 25126039, PMID 25136550, PMID 25171195, PMID 25232509
2023 (2), 2009 (1), 2016 (1), 2019 (1), 2025 (1), R01HL098045 (1), R01HL120909 (1), R01HL179077 (1), R44NS040597 (1), U01HL068060 (1), U10HD036790 (1), U24HL140412 (1), UG1HD021364 (1), UG1HD027851 (1), UG1HD027853 (1)